Our Approach: Data Over Drama
Side effect discussions in the TRT space tend to fall into two unhelpful extremes. Clinic marketing minimizes risks to avoid scaring away customers. Anti-TRT commentary exaggerates risks to discourage therapy. Neither serves you well.
What follows are real incidence rates from clinical studies and trials. Every side effect listed has been documented in peer-reviewed research. We also explain how each one is monitored and managed — because the difference between a dangerous side effect and a manageable one is almost always the quality of clinical oversight.
Erythrocytosis (Blood Thickening): 11–20%
This is the most clinically significant side effect of injectable TRT, and the one that makes regular bloodwork non-negotiable.
What happens: Testosterone potently stimulates erythropoiesis — the production of red blood cells in your bone marrow. In 11–20% of men receiving sustained injectable therapy, red blood cell mass increases to the point where hematocrit (the percentage of blood volume occupied by red blood cells) exceeds safe levels.
Why it matters: Elevated hematocrit dramatically increases blood viscosity. Thick blood flows poorly, increasing the risk of deep vein thrombosis, pulmonary embolism, stroke, and other cardiovascular events. This is not a theoretical risk — it's the primary safety concern of TRT and the reason clinical guidelines mandate ongoing hematocrit monitoring.
The threshold: Clinical protocols universally require intervention if hematocrit reaches or exceeds 52%. Some providers set a more conservative action threshold at 50%.
How it's managed: Therapeutic phlebotomy (essentially blood donation) is the first-line intervention. Dose reduction or switching from injections to a delivery method with lower erythropoietic stimulation (gels or creams) may also be used. The key is catching it early through regular bloodwork — which is why we evaluate clinics heavily on their lab monitoring cadence in our clinic reviews.
Estrogenic Side Effects: 10–25%
What happens: A fraction of testosterone is converted to estradiol (estrogen) by the aromatase enzyme, located primarily in adipose tissue. In genetically susceptible men or those with higher body fat, this conversion can push estradiol above the healthy male reference range (typically above 42.6 pg/mL).
Symptoms: Gynecomastia (breast tissue proliferation) occurs in approximately 10–25% of men on TRT. Water retention, mood swings, reduced libido (paradoxically — high estrogen can suppress the libido improvements testosterone provides), and emotional lability are also common estrogen-related complaints.
How it's managed: Modern endocrinology strongly discourages routine prophylactic use of aromatase inhibitors (like anastrozole). Estradiol is vital for men — it supports bone density, cardiovascular health, brain function, and joint health. Crushing estrogen with aggressive AI dosing causes its own serious problems.
The current standard of care: monitor estradiol on follow-up labs. If it's elevated AND you're experiencing symptoms, your provider may adjust your injection frequency (more frequent, smaller doses reduce estrogen conversion) or prescribe a low-dose aromatase inhibitor titrated to your bloodwork. For the full picture, see our estrogen management guide.
Acne and Skin Changes
What happens: Androgens stimulate sebaceous gland activity, increasing oil production in the skin. This is especially common during the first 3–6 months of therapy as hormone levels are being optimized.
Severity: Most men experience mild to moderate acne that resolves as levels stabilize. Severe cystic acne is less common but possible, particularly at higher doses or in men with a history of acne.
How it's managed: Topical treatments (benzoyl peroxide, salicylic acid, retinoids) handle most cases. If acne persists beyond the stabilization phase, it may indicate your dose is too high. Hair thinning can also occur in men genetically predisposed to androgenic alopecia — exogenous testosterone accelerates this process but doesn't cause it in men without the genetic susceptibility.
Cardiovascular Risk: The TRAVERSE Trial
For years, the biggest fear surrounding TRT was cardiovascular risk. Several observational studies published between 2010 and 2014 suggested increased rates of heart attacks and strokes in men using testosterone, prompting the FDA to mandate a black-box warning on all testosterone products in 2015.
That narrative has been fundamentally updated. The TRAVERSE trial — a landmark randomized, double-blind, placebo-controlled study involving 5,246 men with hypogonadism and pre-existing cardiovascular disease or high cardiovascular risk — provided definitive data.
The key finding: Major adverse cardiovascular events (MACE) — cardiovascular death, nonfatal heart attack, or nonfatal stroke — occurred in 7.0% of the testosterone group versus 7.3% of the placebo group. TRT was statistically non-inferior to placebo for cardiovascular events. In February 2025, the FDA removed the cardiovascular risk language from testosterone product labels.
What was added: The TRAVERSE trial did find small but statistically significant increases in blood pressure (a minimal +0.3 mmHg systolic difference), nonfatal arrhythmias (5.2% vs 3.3%), atrial fibrillation (3.5% vs 2.4%), and acute kidney injury (2.3% vs 1.5%). These findings led to new monitoring recommendations rather than contraindications.
We dive deeper into the TRAVERSE trial in our dedicated article: Is TRT Safe Long-Term?
Fertility Suppression: Near-Universal
This is not a "side effect" in the traditional sense — it's a predictable physiological consequence of how exogenous testosterone works. When your body detects incoming testosterone, it shuts down the hypothalamic-pituitary-gonadal (HPG) axis. Your pituitary stops producing LH and FSH, and without those signals, your testes stop producing sperm and endogenous testosterone.
The result: Significant reduction in sperm count and testicular volume. The American Urological Association explicitly states that exogenous testosterone should not be prescribed as monotherapy to men trying to conceive, because it functions as an effective male contraceptive.
How it's managed: HCG (250–500 IU, 2–3x per week) maintains intratesticular testosterone production and spermatogenesis. Enclomiphene provides an alternative pathway for some patients. Clinics that proactively address fertility — like Maximus — integrate these medications from the start. For the complete picture, see our TRT and fertility guide.
Other Documented Effects
Sleep apnea: TRT can worsen underlying obstructive sleep apnea (OSA). OSA combined with TRT creates a dangerous feedback loop — hypoxia from apnea episodes worsens erythrocytosis, compounding the blood-thickening effect. Clinical guidelines mandate OSA screening before starting TRT. More in our TRT and sleep guide.
Testicular atrophy: Without HCG or similar interventions, testicular volume can decrease significantly (up to 80% in prolonged use) as the testes receive no stimulation from LH. Functionally manageable but psychologically distressing for some men.
Mood changes: While TRT generally improves mood and reduces depression, some men experience irritability or mood instability during the adjustment period — particularly if estrogen levels spike. Proper monitoring and dosing resolve most cases.
How Good Clinics Manage These Risks
Every side effect listed above is manageable with proper clinical oversight. The men who run into serious problems are typically those receiving TRT without adequate monitoring — either from providers who don't require regular labs, or from self-sourced testosterone without medical supervision.
When evaluating a clinic, ask these specific questions:
How often do you check hematocrit? Should be at baseline, 6–12 weeks after starting, and at least every 6 months ongoing.
Do you monitor estradiol? Should be part of every follow-up panel. Clinics that don't check E2 are missing one of the most common causes of side effects.
What's your protocol for elevated hematocrit? The answer should involve phlebotomy and/or dose adjustment — not "we'll keep an eye on it."
Do you screen for sleep apnea? Should be part of the initial evaluation.
Our clinic comparison evaluates providers on exactly these criteria — because the quality of monitoring is what separates safe TRT from risky TRT.